Invest1 distinct publisher3 min readUpdated
Korea's grey channel for weight-loss drugs now dwarfs the licensed one by case count, and a foreign web price that domestic prescriptions cannot match is doing the work.
The Investor · Invest desk

Compiled by The InvestorSomething wrong?How this is made
The ratio buried in the customs numbers is wider than the raw case counts get credit for. Cumulative seizures against cumulative licensed clearances is close to nine to one [1]. Take only the first half of this year and it is about eleven to one [2]. The licensed route is not collapsing, though: its 391 shipments in six months annualise to roughly 782, about four times the 191 logged for all of last year [3]. Both channels are growing. The unofficial one is compounding faster, at a first-half run rate of around 8,310 cases, seven times the 2025 figure [4].
The two sides of that ratio are not the same unit, and the difference cuts against the alarm. Customs is counting intercepted attempts on one side and consignments cleared by importers on the other. A licensed importer's shipment is wholesale volume; a seized international parcel is one person's month or two. Nine to one describes how many buyers are trying, not how many doses actually cross.
On price, sedaily puts a month's supply at about 150,000 won on foreign websites, with some listings at 70,000 to 100,000 won [5][6]. The cheap end sits 33 to 53 percent below the typical foreign figure [5], so buyers are not shopping against a single overseas price but against a spread. The domestic comparison in the report is the loose part: 150,000 won is described as, in some cases, more than half the price of a domestic prescription, which reads as a saving of more than half rather than a price above half [5]. Either reading leaves the gap large enough to move volume.
Everything caught at clearance is held and destroyed in full, with no partial quantity to fall back on [11], and the customs service treats unauthorised import as a Customs Act offence [12]. Each parcel is therefore a wager where the downside is the entire purchase. Cases multiplied anyway [1], which is a revealed estimate of the odds: buyers are acting as though the chance of interception, times the price paid, is still smaller than the domestic bill. The number that would test that belief is not in this dataset. Customs publishes catches, not attempts, so the pass-through rate is unknown to the agency and to the buyers alike.
Classification is what turns the price gap into a crime statistic. Ordinary medicines get a personal allowance of six bottles or a three-month supply [9]; these two get nothing at any quantity without a recommendation letter exempting them from import requirement verification [10]. There is no legal version of paying the foreign price, so the border absorbs the difference one mailbag at a time.
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
A month's supply of Wegovy or Mounjaro can be bought on foreign websites for about 150,000 won, described as in some cases more than half the price of buying with a domestic prescription.
On some foreign websites, a month's supply has reportedly been purchased for 70,000 to 100,000 won.
The Korea Customs Service said it caught 4,155 illegal imports of weight-loss drugs, including Mounjaro and Wegovy, in the first six months of this year, 3.5 times the 1,189 cases recorded for all of last year.
Illegal import cases were four in 2024 and 1,189 last year, and topped 4,000 in the first half of this year; cumulative cases from 2024 through the first half of this year totalled 5,348.
Only 596 shipments cleared customs through licensed importers over the same period: 14 cases in 2024, 191 last year and 391 in the first half of this year.
Cases caught in international mail rose from two in 2024 to 1,046 last year and 3,489 in the first half of this year, accounting for 84.8% of all cumulative cases.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Single official dataset, granular but unverified
The numbers are specific, internally consistent across years and channels, and attributed to the Korea Customs Service, which is the authoritative counter of its own seizures. But the cluster has exactly one publisher and no independent corroboration, no MFDS or manufacturer confirmation, and the price figures are indicative and hedged as 'reportedly'. Case counts also conflate parcel flow with inspection intensity, which the source never addresses.
Grey channel demonstrably at scale and compounding
This is not a proposed behaviour but an observed one, quantified across three years and four channels: 5,348 cumulative interceptions, 3,489 mail cases in six months, 656 hand-carried cases, and a licensed channel simultaneously growing to an annualised 782. Real people are transacting on offshore sites at scale in a major market. It falls short of the top band because interceptions measure attempts caught, not completed purchases or volumes, so true grey-channel size is unknown.
Arithmetic holds, framing outruns the units
The headline growth multiples are straightforwardly supported by the agency's own figures, so this is not inflated storytelling. The modest positive gap comes from two framing stretches: the nine-to-one grey-versus-licensed comparison sets individual parcels against importer shipment clearances, which are not equivalent units and therefore do not measure market share, and the price-gap explanation for the surge is asserted without demand or domestic-price data. Rising enforcement effort as a partial driver of rising case counts is never considered.
Enforcement agency publicising its own enforcement
The dataset, the interpretation and the deterrent messaging all come from the Korea Customs Service, which benefits from demonstrating vigilance and from deterring would-be importers, and closes the report with an explicit warning about Customs Act penalties. Metrics chosen - cases caught, full destruction of seized goods - flatter enforcement activity. No countervailing voice from importers, manufacturers, patients or the Ministry of Food and Drug Safety appears, and the single relaying publisher adds no adversarial check.
Facts firm, interpretation thin
Confidence is moderate: the primary counts are precise, official and unlikely to be wrong in direction, and the regulatory regime described is checkable and specific. What limits confidence is the absence of any second source, the missing denominators (volumes, values, domestic prices, enforcement resourcing) needed to interpret the counts, and reliance on the interested party for both data and causal explanation.
invest
Amgen drops AMG 513 for MariTide, and the obesity field narrows to a Phase 3 shortlist1 distinct publisher
science
Why GIP agonists and antagonists both cut weight: two brain regions, not one contradiction1 distinct publisher
invest
Korea's weight-drug depression finding rests on 846 users. The 4.2x ideation number on fewer.1 distinct publisher
science
An FDA panel wants unapproved peptides sold by prescription. That is deregulation, not wellness.1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
en.sedaily.com
1 article · August 23, 2026